title: Laser chemotherapy of human carcinoma cells with three new anticancer drugs.
abstract: A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 micrograms/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2-fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drug dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.
authors.affiliation: Department of Head and Neck Surgery, Groupe Hospitalier Pitie-Salpetriere, Paris, France.
authors.forename: A A
authors.initials: AA
authors.lastname: Eshraghi
authors.forename: D J
authors.initials: DJ
authors.lastname: Castro
authors.forename: M B
authors.initials: MB
authors.lastname: Paiva
authors.forename: I P
authors.initials: IP
authors.lastname: Graeber
authors.forename: N
authors.initials: N
authors.lastname: Jongewaard
authors.forename: S
authors.initials: S
authors.lastname: Arshadnia
authors.forename: G
authors.initials: G
authors.lastname: Lamas
authors.forename: J
authors.initials: J
authors.lastname: Soudant
authors.forename: R E
authors.initials: RE
authors.lastname: Saxton
mesh_terms: D000873:Anthracenes; D000880:Anthraquinones / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000528:radiation effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D053685:Laser Therapy; D009354:Neodymium; D010569:Perylene / Q000031:analogs & derivatives / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D010710:Phosphates; D010778:Photochemotherapy / Q000379:methods*; D011720:Pyrazoles / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D047069:Pyrazolones; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology* / Q000528:radiation effects / Q000627:therapeutic use; D014025:Titanium; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects
chemical_list: D000873:Anthracenes; D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; C110426:DUP 840; D007546:Isoquinolines; D010710:Phosphates; D011720:Pyrazoles; D047069:Pyrazolones; D011838:Radiation-Sensitizing Agents; C064806:potassium titanylphosphate; D009354:Neodymium; C050637:losoxantrone; D010569:Perylene; C004965:hypericin; D014025:Titanium